Yu-Man Tsui
Overview
Explore the profile of Yu-Man Tsui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
657
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xie X, Tsui Y, Zhang V, Yu T, Husain A, Chiu Y, et al.
Cell Death Dis
. 2025 Feb;
16(1):123.
PMID: 39984455
Germline mutations of the deubiquitinase BRCA1-associated protein 1 (BAP1) lead to the "BAP1 cancer syndrome" characterized by development of cancers. However, the role of BAP1 in hepatocellular carcinoma (HCC) is...
2.
Lyu X, Tsui Y, Tam I, Li P, Cheung G, Lee J, et al.
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272870
Mitochondria generate energy to support cells. They are important organelles that engage in key biological pathways. The dysfunction of mitochondria can be linked to hepatocarcinogenesis, which has been actively explored...
3.
Tsui Y, Tian L, Lu J, Ma H, Ng I
Cancer Lett
. 2024 Jun;
597:217084.
PMID: 38925362
The intricate interplay among extracellular vesicles, cancer stemness properties, and the immune system significantly impacts hepatocellular carcinoma (HCC) progression, treatment response, and patient prognosis. Extracellular vesicles (EVs), which are membrane-bound...
4.
Tsui Y, Ho D, Sze K, Lee J, Lee E, Zhang Q, et al.
Cell Mol Gastroenterol Hepatol
. 2024 May;
18(3):101358.
PMID: 38750898
Background & Aims: Hepatocellular carcinoma (HCC) is a heterogeneous cancer with varying levels of liver tumor initiating or cancer stem cells in the tumors. We aimed to investigate the expression...
5.
Cheung T, Ho D, Lyu S, Zhang Q, Tsui Y, Yu T, et al.
Liver Cancer
. 2024 Feb;
13(1):70-88.
PMID: 38344450
Introduction: Immunotherapy has resulted in pathologic responses in hepatocellular carcinoma (HCC), but the benefits and molecular mechanisms of neoadjuvant immune checkpoint blockade are largely unknown. Methods: In this study, we...
6.
Zhang Q, Tsui Y, Zhang V, Lu A, Lee J, Lee E, et al.
Theranostics
. 2024 Jan;
14(2):892-910.
PMID: 38169544
The tumor microenvironment of cancers has emerged as a crucial component in regulating cancer stemness and plays a pivotal role in cell-cell communication. However, the specific mechanisms underlying these phenomena...
7.
Huang H, Tsui Y, Ho D, Chung C, Sze K, Lee E, et al.
Hepatology
. 2023 Aug;
79(2):323-340.
PMID: 37540188
Background And Aims: HCC is an aggressive cancer with a poor clinical outcome. Understanding the mechanisms that drive tumor initiation is important for improving treatment strategy. This study aimed to...
8.
Kam C, Ho D, Ming V, Tian L, Sze K, Zhang V, et al.
Cell Mol Gastroenterol Hepatol
. 2023 Feb;
15(6):1325-1350.
PMID: 36806581
Background & Aims: Metabolic reprogramming is recognized as a cancer hallmark intimately linked to tumor hypoxia, which supports rapid tumor growth and mitigates the consequential oxidative stress. Phosphofructokinase-fructose bisphosphatase (PFKFB)...
9.
Huang H, Tsui Y, Ng I
Cell Mol Gastroenterol Hepatol
. 2023 Feb;
15(5):1105-1116.
PMID: 36736664
Liver cancer (hepatocellular carcinoma) is a common cancer worldwide. It is an aggressive cancer, with high rates of tumor relapse and metastasis, high chemoresistance, and poor prognosis. Liver tumor-initiating cells...
10.
Wang X, Huang H, Sze K, Wang J, Tian L, Lu J, et al.
Gut
. 2023 Jan;
72(7):1370-1384.
PMID: 36631249
Objective: Growing evidence indicates that tumour cells exhibit characteristics similar to their lineage progenitor cells. We found that S100 calcium binding protein A10 (S100A10) exhibited an expression pattern similar to...